Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Elutia’s filings can feel like untangling lab notes—clinical trial updates, device-tissue interaction data, and shifting FDA timelines are buried inside hundreds of pages. If you have ever searched for “Elutia SEC filings explained simply” or wondered how a single footnote can change the outlook for drug-eluting biomatrix sales, you are not alone.
Stock Titan solves this problem. Our AI parses every document the moment it hits EDGAR, turning dense text into clear takeaways. Need the Elutia quarterly earnings report 10-Q filing to spot Women’s Health revenue trends? We highlight them in seconds. Tracking Elutia insider trading Form 4 transactions? Real-time alerts flag each executive stock move, so you catch patterns before the market reacts.
All filing types are here—10-K, 10-Q, 8-K, S-1, and the proxy statement—each paired with concise, plain-language summaries:
- 10-K annual report: See R&D spend, segment margins, and risk factors in our “Elutia annual report 10-K simplified” view.
- Form 4 insider activity: Drill into “Elutia Form 4 insider transactions real-time” to gauge leadership confidence.
- 8-K material events: Follow trial results or distribution deals under “Elutia 8-K material events explained”.
- Proxy statement: Compare “Elutia proxy statement executive compensation” against peer med-tech firms.
Use cases span monitoring device-protection adoption, evaluating cardiovascular pipeline milestones, and verifying regulatory progress—all without wading through jargon. From “Elutia earnings report filing analysis” to “understanding Elutia SEC documents with AI,” Stock Titan gives you the context, numbers, and narrative you need to act confidently.
Elutia Inc. announced the closing of a sale of substantially all assets related to its cardiac implantable electronic device (CIED) business to Boston Scientific Corporation and Cardiac Pacemakers, Inc., under an Asset Purchase Agreement dated
Elutia Inc. (ELUT) Chief Scientific Officer Michelle LeRoux Williams reported the vesting of restricted stock units on 09/10/2025 that resulted in the acquisition of 12,500 shares of Class A common stock. The filing shows 3,950 shares were withheld to satisfy tax withholding, leaving the reporting person with 97,335 shares beneficially owned after the transaction. The underlying RSU grant of 150,000 was originally made on January 31, 2024, with a defined multi-quarter vesting schedule through December 10, 2026.
Matthew Ferguson, Chief Financial Officer of Elutia Inc. (ELUT), reported insider transactions dated 09/10/2025. On that date he received 29,000 shares of Class A Common Stock upon vesting of restricted stock units, which increased his beneficial ownership to 379,417 shares. The filing also shows 10,348 shares were withheld to satisfy tax withholding at a reported price of $1.36, reducing the reported holding to 369,069 shares. The filing discloses the original RSU grants made on January 31, 2024 (150,000 and 50,000 RSUs) and the vesting schedules for those grants. The form is signed by Mr. Ferguson on 09/11/2025.
C. Randal Mills, who serves as President, Chief Executive Officer and a director of Elutia Inc. (ELUT), reported the vesting of 27,083 restricted stock units (RSUs) on 09/10/2025. Those vested RSUs converted into Class A common stock and are reported as an acquisition. The issuer withheld 9,664 shares to satisfy tax withholding at an indicated withholding price of $1.36 per share.
Following these transactions the filing shows the reporting person beneficially owning 338,586 shares of Class A common stock. The filing also discloses that on January 31, 2024 the reporting person was granted 487,500 RSUs, of which 297,916 RSUs are shown as derivative securities still outstanding and subject to the vesting schedule described in the filing.
Elutia Inc. disclosed that it entered into a Fifth Amendment to the Credit Agreement dated August 14, 2025 among Elutia Inc., SWK Funding LLC (as Agent) and the lenders party thereto. The 8-K lists this amendment as an exhibit (Exhibit 10.1) and cites Items 1.01 (entry into a material definitive agreement) and 2.03 (creation of a direct financial obligation or off-balance-sheet arrangement). The filing includes an Inline XBRL cover page (Exhibit 104). The document provides the existence and date of the amendment but does not disclose the amendment's terms, financial amounts, covenants, maturity changes, or other transactional details.
Elutia, Inc. reported continued operating losses and significant legal and liquidity risks in its Form 10-Q. For the six months ended June 30, 2025, the company recorded a net loss of $13.5 million and an accumulated deficit of $243.1 million. Cash used in operations totaled $17.1 million year-to-date and the company expects ongoing cash outflows for the rest of 2025, raising concerns about its ability to achieve and sustain profitability.
The company completed the sale of its Orthobiologics Business (initial gain recognized of $6.0 million in 2023 and an additional $0.2 million in 2024) with potential earn-outs of up to $20 million and a $1.5 million indemnity holdback. Material litigation includes extensive FiberCel and VBM claims: the company recorded $13.3 million as a probable liability for 47 FiberCel cases and $3.7 million for VBM-related matters, with substantial settlements already paid and insurance receivables recorded. Elutia has a secured SWK loan facility with a weighted average interest rate of 12.6% for the three months ended June 30, 2025 and amended covenants requiring a minimum liquidity of $8.0 million. The company discloses substantial risks around commercialization of EluPro, supplier dependence, indemnities and contingent liabilities.
Form 4 overview: On 06/21/2025 Elutia Inc. (ELUT) filed a Form 4 detailing equity activity by President & CEO C. Randal Mills, who is also a director.
Transactions:
- 22,473 Class A shares were acquired through the vesting and settlement of an equal number of restricted stock units (RSUs) (Code “M”).
- 8,019 shares were withheld at $1.81 per share to satisfy tax obligations (Code “F”).
The net increase to the executive’s direct holdings is 14,454 shares.
Post-transaction ownership: Mills now directly owns 321,167 Class A shares. Table II shows 22,473 RSUs still outstanding, indicating additional shares may be delivered in future periods.
Award background: The underlying RSU grant was issued on 06/21/2022 for 89,893 units, vesting in four equal annual tranches beginning 06/21/2023. The current filing represents the second scheduled vesting installment.
No open-market purchases or sales occurred, and the form does not cite a Rule 10b5-1 plan. As such, the disclosure reflects a routine insider vesting event with limited immediate market impact for investors.
FAQ
What is the current stock price of Elutia (ELUT)?
What is the market cap of Elutia (ELUT)?
